{"id":"restasis-cyclosporine-0-05","safety":{"commonSideEffects":[{"rate":"null","effect":"Eye irritation"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Eye pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Restasis contains cyclosporine, an immunosuppressant that helps to increase tear production by reducing inflammation in the lacrimal gland. This leads to improved tear quality and quantity, alleviating symptoms of dry eye syndrome.","oneSentence":"Restasis works by increasing tear production in patients with dry eye syndrome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:54.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of chronic dry eye syndrome"}]},"trialDetails":[{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":"Dry Eye Disease (DED), Cataract","enrollment":55},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT06981104","phase":"NA","title":"Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-18","conditions":"Dry Eye Disease (DED), Asthenopia","enrollment":60},{"nctId":"NCT07171710","phase":"NA","title":"Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Eye Hospital","startDate":"2024-03-01","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT06944132","phase":"NA","title":"CsA vs MMC for Preventing Pterygium Recurrence","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-04-01","conditions":"Pterygium, Pterygium of the Conjunctiva and Cornea","enrollment":40},{"nctId":"NCT04988256","phase":"EARLY_PHASE1","title":"Cyclosporine Vs Steroids in DRESS","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2021-09-27","conditions":"DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome","enrollment":50},{"nctId":"NCT06876116","phase":"PHASE4","title":"Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dry Eye Disease (DED)","enrollment":32},{"nctId":"NCT06824844","phase":"PHASE4","title":"The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-12-02","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT04918823","phase":"PHASE1, PHASE2","title":"Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device","status":"COMPLETED","sponsor":"Boston Sight","startDate":"2021-07-15","conditions":"Ocular Surface Disease","enrollment":10},{"nctId":"NCT06624384","phase":"PHASE1","title":"Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024","status":"NOT_YET_RECRUITING","sponsor":"Mohsen Pourazizi","startDate":"2024-10-30","conditions":"Ocular Surface Symptom, Ocular Surface Disease, Eye Pain","enrollment":150},{"nctId":"NCT05743764","phase":"PHASE3","title":"HU007 in Patients with Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2023-03-23","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT05720715","phase":"PHASE4","title":"Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2022-01-01","conditions":"Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis","enrollment":30},{"nctId":"NCT00110110","phase":"PHASE2","title":"Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2004-06","conditions":"Retinoblastoma","enrollment":71},{"nctId":"NCT05184517","phase":"EARLY_PHASE1","title":"A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers","status":"COMPLETED","sponsor":"OphRx Ltd.","startDate":"2023-01-23","conditions":"Dry Eye Syndromes","enrollment":20},{"nctId":"NCT04357795","phase":"PHASE4","title":"Effect of Cequa™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-06-29","conditions":"Dry Eye Disease","enrollment":135},{"nctId":"NCT05733624","phase":"PHASE2","title":"Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis","status":"COMPLETED","sponsor":"SCAI Therapeutics","startDate":"2023-01-05","conditions":"Dry Eye Syndromes","enrollment":116},{"nctId":"NCT05627947","phase":"PHASE1","title":"Comparison Between Topical Mitomycin C and Cyclosporine","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2021-01-01","conditions":"Pterygium","enrollment":57},{"nctId":"NCT06043908","phase":"PHASE4","title":"The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-08-31","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT06013436","phase":"","title":"AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2022-06-01","conditions":"Sjogren's Syndrome, Dry Eye, Ocular Surface Disease","enrollment":30},{"nctId":"NCT04735510","phase":"PHASE3","title":"Novel Use of Restasis and PROSE Devices","status":"WITHDRAWN","sponsor":"Boston Sight","startDate":"2021-05","conditions":"Ocular Surface Disease","enrollment":""},{"nctId":"NCT05771012","phase":"NA","title":"Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2021-01-01","conditions":"Management of Punctal Stenosis","enrollment":42},{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT04127851","phase":"PHASE4","title":"Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2019-11-12","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":438},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT05294666","phase":"PHASE4","title":"Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2020-04-01","conditions":"Graft Versus Host Disease in Eye","enrollment":89},{"nctId":"NCT05245604","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2020-06-19","conditions":"Dry Eye Syndrome","enrollment":182},{"nctId":"NCT05131152","phase":"NA","title":"Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-12-01","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT03597139","phase":"PHASE2","title":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2018-08-13","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT04714099","phase":"PHASE3","title":"Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2015-01-01","conditions":"Dry Eye","enrollment":40},{"nctId":"NCT04637633","phase":"PHASE2, PHASE3","title":"Topical Cyclosporine-A for Management of Epiphora","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2020-08-15","conditions":"Epiphora","enrollment":12},{"nctId":"NCT02004067","phase":"PHASE4","title":"Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-01","conditions":"Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease","enrollment":100},{"nctId":"NCT04384991","phase":"PHASE3","title":"HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2019-05-03","conditions":"Dry Eye Syndromes","enrollment":216},{"nctId":"NCT03461575","phase":"PHASE3","title":"Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2018-01-22","conditions":"Dry Eye Syndrome","enrollment":209},{"nctId":"NCT02199964","phase":"NA","title":"The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2014-03","conditions":"Dry Eye","enrollment":4},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT03865888","phase":"PHASE3","title":"Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome","status":"COMPLETED","sponsor":"Pavly Moawd","startDate":"2018-10-30","conditions":"Dry Eye, Sjogren Syndrome","enrollment":60},{"nctId":"NCT00827255","phase":"","title":"Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":35},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT01768312","phase":"PHASE3","title":"Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2012-08-23","conditions":"Dry Eye Syndromes","enrollment":84},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT02917512","phase":"PHASE2","title":"Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-03","conditions":"Dry Eye Syndrome","enrollment":114},{"nctId":"NCT00987467","phase":"NA","title":"Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-08","conditions":"Atopic Keratoconjunctivitis","enrollment":12},{"nctId":"NCT03403023","phase":"NA","title":"Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2018-01-30","conditions":"Dry Eye Syndrome, Tear Film Insufficiency","enrollment":40},{"nctId":"NCT02653196","phase":"EARLY_PHASE1","title":"A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2015-09","conditions":"Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":1},{"nctId":"NCT03192657","phase":"PHASE2","title":"Basiliximab Treating Interstitial Pneumonia of CADM","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-07","conditions":"Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis","enrollment":100},{"nctId":"NCT00157014","phase":"PHASE3","title":"Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-05-10","conditions":"Heart Diseases, Heart Transplantation","enrollment":111},{"nctId":"NCT02554981","phase":"PHASE4","title":"Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-07-21","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT00553735","phase":"PHASE4","title":"The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2007-08","conditions":"Dry Eye","enrollment":8},{"nctId":"NCT01064830","phase":"PHASE2","title":"Topical Cyclosporine Suspension for the Treatment of Brittle Nails","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-02","conditions":"Brittle Nail Syndrome","enrollment":21},{"nctId":"NCT00405431","phase":"NA","title":"Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2004-03","conditions":"Glaucoma","enrollment":43},{"nctId":"NCT01198782","phase":"PHASE4","title":"Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":48},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT00983645","phase":"PHASE4","title":"A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity","status":"TERMINATED","sponsor":"Loma Linda University","startDate":"2004-10","conditions":"Renal Transplant Rejection","enrollment":15},{"nctId":"NCT01319773","phase":"PHASE1","title":"Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT01804361","phase":"PHASE3","title":"Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes","status":"COMPLETED","sponsor":"DH Bio Co., Ltd.","startDate":"2013-03","conditions":"Dry Eye Syndromes","enrollment":90},{"nctId":"NCT02492412","phase":"PHASE3","title":"Efficacy and Safety of HE10 for Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2013-05","conditions":"Dry Eye Syndrome","enrollment":101},{"nctId":"NCT02461719","phase":"PHASE3","title":"Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2014-01","conditions":"Dry Eye Syndromes","enrollment":158},{"nctId":"NCT02229955","phase":"PHASE3","title":"Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2013-12","conditions":"Dry Eye Syndromes","enrollment":86},{"nctId":"NCT02147509","phase":"NA","title":"Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome","status":"COMPLETED","sponsor":"Jinyang Li","startDate":"2013-03","conditions":"Sjögren's Syndrome Patients With Severe Dry Eye","enrollment":64},{"nctId":"NCT00986427","phase":"PHASE2","title":"Restasis for Treatment of Brittle Nails","status":"COMPLETED","sponsor":"Julian M. Mackay-Wiggan","startDate":"2009-07","conditions":"Brittle Nails","enrollment":24},{"nctId":"NCT00784719","phase":"PHASE1, PHASE2","title":"A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Dry Eye Syndromes","enrollment":327},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Epiphora","enrollment":""},{"nctId":"NCT01109056","phase":"PHASE2","title":"Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Pterygium","enrollment":115},{"nctId":"NCT00717418","phase":"","title":"Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-09","conditions":"Keratoconjunctivitis Sicca","enrollment":781},{"nctId":"NCT00611403","phase":"PHASE2","title":"Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Dry Eye Syndromes","enrollment":137},{"nctId":"NCT01488396","phase":"PHASE4","title":"Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2007-02","conditions":"Stevens-Johnson Syndrome","enrollment":31},{"nctId":"NCT01429844","phase":"PHASE3","title":"Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2001-01","conditions":"Bronchiolitis Obliterans, Immunosuppression","enrollment":274},{"nctId":"NCT00348335","phase":"PHASE4","title":"Efficacy of Topical Cyclosporin for Ocular Rosacea","status":"COMPLETED","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2006-06","conditions":"Rosacea","enrollment":35},{"nctId":"NCT00705510","phase":"PHASE4","title":"Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-05","conditions":"Meibomian Gland Dysfunction","enrollment":70},{"nctId":"NCT00426023","phase":"PHASE3","title":"Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2007-02","conditions":"Vernal Keratoconjunctivitis","enrollment":48},{"nctId":"NCT00797030","phase":"PHASE4","title":"Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus","status":"UNKNOWN","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2006-10","conditions":"Dry Eye Syndromes, HIV Seropositivity","enrollment":20},{"nctId":"NCT00704275","phase":"PHASE4","title":"Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2007-06","conditions":"Dry Eye","enrollment":60},{"nctId":"NCT00383396","phase":"PHASE4","title":"Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Pterygia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Restasis (cyclosporine 0.05%)","genericName":"Restasis (cyclosporine 0.05%)","companyName":"DH Bio Co., Ltd.","companyId":"dh-bio-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Restasis works by increasing tear production in patients with dry eye syndrome. Used for Treatment of chronic dry eye syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}